Munich, Georgia

Guillaume Le Baut


Average Co-Inventor Count = 6.9

ph-index = 2

Forward Citations = 18(Granted Patents)


Location History:

  • Saint Sebastien/Loire, FR (2002)
  • Saint Sebastian/Loire, DE (2009)

Company Filing History:


Years Active: 2002-2009

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations of Guillaume Le Baut

Introduction

Guillaume Le Baut is a notable inventor based in Munich, Germany. He has made significant contributions to the field of pharmaceuticals, particularly in the development of antitumor agents. With a total of two patents to his name, his work has the potential to impact cancer treatment.

Latest Patents

Guillaume Le Baut's latest patents include "Indolyl-3-glyoxylic acid derivatives having antitumor action." This invention relates to the use of N-substituted indole-3-glyoxylamides as antitumor agents. The pharmaceutical composition he developed contains these compounds, which may also exist in the form of physiologically tolerable acid addition salts or N-oxides. Additionally, he has patented "Substituted N-benzylindol-3-ylglyoxylic acid derivatives having antitumor action," further expanding the arsenal of potential cancer treatments.

Career Highlights

Throughout his career, Guillaume Le Baut has worked with several prominent companies in the pharmaceutical industry. Notable among these are Zentaris AG and Ziopharm Oncology, Inc. His experience in these organizations has contributed to his expertise in developing innovative therapeutic solutions.

Collaborations

Guillaume has collaborated with esteemed colleagues such as Peter Emig and Dietmar Reichert. These partnerships have likely enhanced his research and development efforts in the field of oncology.

Conclusion

Guillaume Le Baut's contributions to the field of antitumor agents demonstrate his commitment to advancing cancer treatment. His innovative patents and collaborations highlight his role as a significant figure in pharmaceutical research.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…